�Biotechnology company Arana Therapeutics Limited (ASX: AAH) announced that it has completed recruitment in its Phase II dose-ranging psoriasis study for its anti-inflammatory do drugs ART621. Completion of recruitment means that formal results of the study should be usable in former 2009.
Arana also confirmed that it is planning to submit an Investigational New Drug (IND) lotion for ART621 in the rheumatoid arthritis indication in the fourth quarter of 2008.
Commenting on these developments, CEO John Chiplin said: "We are pleased with the clinical progression of ART621 and ar excited to be finalising the IND documentation, the submission of which is a all important milestone towards the commercialisation of ART621."
"Subject to feedback from the FDA (U.S. Food and Drug Administration), we look onward to the commencement of our rheumatic arthritis programme by the end of this year which we have been carefully planning for some time now." Dr Chiplin said.
ART621 is an "anti-TNF" - a class of drugs used for the treatment of incendiary diseases such as creaky arthritis, psoriasis and Crohn's disease. ART621 works by blocking the action of TNF (neoplasm necrosis factor) a protein which is involved in the contemporaries of rubor.
"We are targeting two of the key anti-TNF markets - rheumatoid arthritis and psoriasis. If successful in trials, the unique nature of our product should enable us to gain a valuable parcel of the large and growing anti-TNF market" Dr Chiplin aforementioned.
The tot market for existing anti-TNF's, Remicade�, Humira� and Enbrel�, was US$12.8 billion in 2007. This market is expected to exceed US$20 billion by 2012.
About Arana Therapeutics
Arana Therapeutics (ASX: AAH) is an international biopharmaceutical fellowship formed through and through the amalgamation of Peptech and EvoGenix in August 2007. The company uses superior engineering to get next contemporaries drugs that will improve the lives of patients with inflammatory diseases and cancer.
Arana Therapeutics' forward-looking engineering technologies provide the basis for clinical growing in the antibody blank space, a market which draws on heights demand. Arana Therapeutics has the financial stability and management expertness to speed its clinical programs.
The pipeline consists of four lead dose programs: ART621 to treat severe rheumatic arthritis and other incendiary diseases; ART010 to handle osteoporosis and bone cancer; ART104 to treat solid tumours in colorectal cancer; and ART150 for lung cancer and melanoma. Additionally the company has sooner stage products in developing for the treatment of a range of conditions including age related macular degeneration, psoriasis, colorectal crab, and leucaemia.
Arana has recurring revenues from commercial and development partnerships with six international companies including GSK, CSL, Centocor (J&J) and Abbott Laboratories.
http://www.arana.com
View drug data on Enbrel; Humira; Remicade.
More info
